IMR Press / FBL / Volume 10 / Issue 3 / DOI: 10.2741/1727

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Chemotherapy and novel therapeutic approaches in malignant glioma
Show Less
1 The Brain Tumor Center, Department of Pediatrics, Duke University Medical Center, 047 Baker House, Trent Drive, Box 3624, Durham, NC 27710, USA

Academic Editor: Keith Black

Front. Biosci. (Landmark Ed) 2005, 10(3), 2645–2668;
Published: 1 September 2005
(This article belongs to the Special Issue New innovations in management of brain tumors)

Glial neoplasms represent 0.5-1% of all cancers in most Western countries. Malignant gliomas are among the most devastating cancers, leading to death in most cases. They present unique challenges due to their location, aggressive biological behavior and diffuse infiltrative growth. Notwithstanding the development of new surgical and radiation techniques in the last thirty years, a cure for malignant gliomas remains elusive. In this article, we will review the standard and new therapies used for malignant gliomas. As standard therapies, surgery, radiation therapy and systemic chemotherapy, are in a continuous process of evolution. Multiple chemotherapies have been used in malignant gliomas, as single agents, in combination, or with different modes of administration, including high-dose chemotherapy with stem cell rescue and intra-arterial chemotherapy. The last decade has been noticeable for the advent of a better understanding of the biology of malignant gliomas. This has stimulated active research in multiples areas and the advent of new treatment strategies. Techniques to circumvent the resistance mechanisms to chemotherapy have been evaluated, tyrosine kinase inhibitors have shown activity in malignant primary brain tumors and radioimmunotherapy remains an area of active research. In this article, we review the past, present and future treatments of malignant gliomas with a special interest on chemotherapy, resistance mechanisms and tyrosine kinase inhibitors.

Glial cells
B rain
malignant gliomas
radiation therapy
tyrosine kinase inhibitors
Back to top